Literature DB >> 30976548

Association between oncogenic RAS mutation and radiologic-pathologic findings in patients with primary rectal cancer.

Sung Jae Jo1, Seung Ho Kim1.   

Abstract

BACKGROUND: To evaluate the association between various radiologic-pathologic findings and oncogenic Kirsten-ras (KRAS) mutation in patients with primary rectal cancer.
METHODS: Seventy-five patients with primary rectal cancer who had undergone rectal magnetic resonance imaging (MRI) were included. The rectal MRI consisted of T2-weighted images in three planes, pre- and post-contrast-enhanced T1-weighted images, and axial diffusion-weighted images (b factors, 0, 1,000 s/mm2). Two radiologists reviewed the MRI scans and measured the axial and longitudinal tumor lengths (LTLs), apparent diffusion coefficient (ADC), and relative contrast enhancement [signal intensity (SI) difference of tumor on pre- and post-contrast T1WI/SI of tumor on pre-contrast T1WI]. The associations among the qualitative data (tumor stage, node stage, lymphatic invasion, venous invasion, and perineural invasion), quantitative data (tumor length, ADC, relative contrast enhancement) and KRAS mutations were statistically analyzed by Fisher's exact test for the qualitative data and by the Mann-Whitney U test for the quantitative data. An area under receiver operating characteristic curve (AUC) was considered as the diagnostic performance for the prediction of KRAS mutation. Molecular-biologic results served as the reference standard.
RESULTS: The ratio of axial to LTL in the KRAS-mutant group (n=41) was higher than that in the wild-type group (n=34) (0.29±0.15; 0.22±0.08, P=0.0117). The AUC was 0.640 (95% CI, 0.520 to 0.747, P=0.0292) with an estimated maximum accuracy of 64%. The mean ADC of the mutant group was not significantly different from that of the wild-type group [(0.95±0.17)×10-3 mm2/s; (0.96±0.17)×10-3 mm2/s, P=0.6505]. The relative contrast enhancement showed no significant difference between the two groups (1.66±0.93, 1.35±0.84, P=0.1581). The other qualitative findings also did not show any significant difference (P>0.05).
CONCLUSIONS: The ratio of axial to LTL showed a significant difference according to KRAS mutation in patients with primary rectal cancer. However, it showed a low accuracy of 64% for prediction of KRAS mutation.

Entities:  

Keywords:  Kirsten-ras (KRAS) mutation; Magnetic resonance imaging (MRI); apparent diffusion coefficient (ADC); rectal neoplasms; relative contrast enhancement

Year:  2019        PMID: 30976548      PMCID: PMC6414762          DOI: 10.21037/qims.2018.12.10

Source DB:  PubMed          Journal:  Quant Imaging Med Surg        ISSN: 2223-4306


  29 in total

1.  Rectal cancer: local staging and assessment of lymph node involvement with endoluminal US, CT, and MR imaging--a meta-analysis.

Authors:  Shandra Bipat; Afina S Glas; Frederik J M Slors; Aeilko H Zwinderman; Patrick M M Bossuyt; Jaap Stoker
Journal:  Radiology       Date:  2004-07-23       Impact factor: 11.105

2.  Imaging for predicting the risk factors--the circumferential resection margin and nodal disease--of local recurrence in rectal cancer: a meta-analysis.

Authors:  M J Lahaye; S M E Engelen; P J Nelemans; G L Beets; C J H van de Velde; J M A van Engelshoven; R G H Beets-Tan
Journal:  Semin Ultrasound CT MR       Date:  2005-08       Impact factor: 1.875

3.  Molecular pathogenesis of colorectal cancer: implications for molecular diagnosis.

Authors:  Christian N Arnold; Ajay Goel; Hubert E Blum; C Richard Boland
Journal:  Cancer       Date:  2005-11-15       Impact factor: 6.860

Review 4.  The EGFR as a target for anticancer therapy--focus on cetuximab.

Authors:  J Baselga
Journal:  Eur J Cancer       Date:  2001-09       Impact factor: 9.162

Review 5.  Predictive and prognostic value of KRAS mutations in metastatic colorectal cancer patients treated with cetuximab: a meta-analysis of 22 studies.

Authors:  Li-Xin Qiu; Chen Mao; Jian Zhang; Xiao-Dong Zhu; Ru-Yan Liao; Kai Xue; Jin Li; Qing Chen
Journal:  Eur J Cancer       Date:  2010-06-25       Impact factor: 9.162

6.  Genetic pathways in the evolution of morphologically distinct colorectal neoplasms.

Authors:  M Yashiro; J M Carethers; L Laghi; K Saito; P Slezak; E Jaramillo; C Rubio; K Koizumi; K Hirakawa; C R Boland
Journal:  Cancer Res       Date:  2001-03-15       Impact factor: 12.701

7.  KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.

Authors:  Astrid Lièvre; Jean-Baptiste Bachet; Valérie Boige; Anne Cayre; Delphine Le Corre; Emmanuel Buc; Marc Ychou; Olivier Bouché; Bruno Landi; Christophe Louvet; Thierry André; Fréderic Bibeau; Marie-Danièle Diebold; Philippe Rougier; Michel Ducreux; Gorana Tomasic; Jean-François Emile; Frédérique Penault-Llorca; Pierre Laurent-Puig
Journal:  J Clin Oncol       Date:  2008-01-20       Impact factor: 44.544

8.  Cetuximab for the treatment of colorectal cancer.

Authors:  Derek J Jonker; Chris J O'Callaghan; Christos S Karapetis; John R Zalcberg; Dongsheng Tu; Heather-Jane Au; Scott R Berry; Marianne Krahn; Timothy Price; R John Simes; Niall C Tebbutt; Guy van Hazel; Rafal Wierzbicki; Christiane Langer; Malcolm J Moore
Journal:  N Engl J Med       Date:  2007-11-15       Impact factor: 91.245

9.  K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

Authors:  Christos S Karapetis; Shirin Khambata-Ford; Derek J Jonker; Chris J O'Callaghan; Dongsheng Tu; Niall C Tebbutt; R John Simes; Haji Chalchal; Jeremy D Shapiro; Sonia Robitaille; Timothy J Price; Lois Shepherd; Heather-Jane Au; Christiane Langer; Malcolm J Moore; John R Zalcberg
Journal:  N Engl J Med       Date:  2008-10-23       Impact factor: 91.245

Review 10.  The significance of unstable chromosomes in colorectal cancer.

Authors:  Harith Rajagopalan; Martin A Nowak; Bert Vogelstein; Christoph Lengauer
Journal:  Nat Rev Cancer       Date:  2003-09       Impact factor: 60.716

View more
  3 in total

Review 1.  Overview of serum and tissue markers in colorectal cancer: a primer for radiologists.

Authors:  Apurva Bonde; Daniel A Smith; Elias Kikano; Jennifer M Yoest; Sree H Tirumani; Nikhil H Ramaiya
Journal:  Abdom Radiol (NY)       Date:  2021-08-20

2.  Pretreatment Apparent Diffusion Coefficient Cannot Predict Histopathological Features and Response to Neoadjuvant Radiochemotherapy in Rectal Cancer: A Meta-Analysis.

Authors:  Alexey Surov; Maciej Pech; Maciej Powerski; Katja Woidacki; Andreas Wienke
Journal:  Dig Dis       Date:  2021-03-04       Impact factor: 2.404

3.  Histological grades of rectal cancer: whole-volume histogram analysis of apparent diffusion coefficient based on reduced field-of-view diffusion-weighted imaging.

Authors:  Yang Peng; Hao Tang; Xiaoyan Meng; Yaqi Shen; Daoyu Hu; Ihab Kamel; Zhen Li
Journal:  Quant Imaging Med Surg       Date:  2020-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.